These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36889611)

  • 1. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19.
    Stone GW; Farkouh ME; Lala A; Tinuoye E; Dressler O; Moreno PR; Palacios IF; Goodman SG; Esper RB; Abizaid A; Varade D; Betancur JF; Ricalde A; Payro G; Castellano JM; Hung IFN; Nadkarni GN; Giustino G; Godoy LC; Feinman J; Camaj A; Bienstock SW; Furtado RHM; Granada C; Bustamante J; Peyra C; Contreras J; Owen R; Bhatt DL; Pocock SJ; Fuster V;
    J Am Coll Cardiol; 2023 May; 81(18):1747-1762. PubMed ID: 36889611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
    Farkouh ME; Stone GW; Lala A; Bagiella E; Moreno PR; Nadkarni GN; Ben-Yehuda O; Granada JF; Dressler O; Tinuoye EO; Granada C; Bustamante J; Peyra C; Godoy LC; Palacios IF; Fuster V
    J Am Coll Cardiol; 2022 Mar; 79(9):917-928. PubMed ID: 35241226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
    Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
    Rentsch CT; Beckman JA; Tomlinson L; Gellad WF; Alcorn C; Kidwai-Khan F; Skanderson M; Brittain E; King JT; Ho YL; Eden S; Kundu S; Lann MF; Greevy RA; Ho PM; Heidenreich PA; Jacobson DA; Douglas IJ; Tate JP; Evans SJW; Atkins D; Justice AC; Freiberg MS
    BMJ; 2021 Feb; 372():n311. PubMed ID: 33574135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
    Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
    J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of randomized controlled trials.
    Meng J; Tang H; Xiao Y; Liu W; Wu Y; Xiong Y; Gao S
    Int J Surg; 2024 Jun; 110(6):3910-3922. PubMed ID: 38549227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis.
    Jorda A; Siller-Matula JM; Zeitlinger M; Jilma B; Gelbenegger G
    Clin Pharmacol Ther; 2022 Mar; 111(3):614-623. PubMed ID: 34862791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
    Billett HH; Reyes-Gil M; Szymanski J; Ikemura K; Stahl LR; Lo Y; Rahman S; Gonzalez-Lugo JD; Kushnir M; Barouqa M; Golestaneh L; Bellin E
    Thromb Haemost; 2020 Dec; 120(12):1691-1699. PubMed ID: 33186991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.
    Bohula EA; Berg DD; Lopes MS; Connors JM; Babar I; Barnett CF; Chaudhry SP; Chopra A; Ginete W; Ieong MH; Katz JN; Kim EY; Kuder JF; Mazza E; McLean D; Mosier JM; Moskowitz A; Murphy SA; O'Donoghue ML; Park JG; Prasad R; Ruff CT; Shahrour MN; Sinha SS; Wiviott SD; Van Diepen S; Zainea M; Baird-Zars V; Sabatine MS; Morrow DA;
    Circulation; 2022 Nov; 146(18):1344-1356. PubMed ID: 36036760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
    ; ; ; Lawler PR; Goligher EC; Berger JS; Neal MD; McVerry BJ; Nicolau JC; Gong MN; Carrier M; Rosenson RS; Reynolds HR; Turgeon AF; Escobedo J; Huang DT; Bradbury CA; Houston BL; Kornblith LZ; Kumar A; Kahn SR; Cushman M; McQuilten Z; Slutsky AS; Kim KS; Gordon AC; Kirwan BA; Brooks MM; Higgins AM; Lewis RJ; Lorenzi E; Berry SM; Berry LR; Aday AW; Al-Beidh F; Annane D; Arabi YM; Aryal D; Baumann Kreuziger L; Beane A; Bhimani Z; Bihari S; Billett HH; Bond L; Bonten M; Brunkhorst F; Buxton M; Buzgau A; Castellucci LA; Chekuri S; Chen JT; Cheng AC; Chkhikvadze T; Coiffard B; Costantini TW; de Brouwer S; Derde LPG; Detry MA; Duggal A; Džavík V; Effron MB; Estcourt LJ; Everett BM; Fergusson DA; Fitzgerald M; Fowler RA; Galanaud JP; Galen BT; Gandotra S; García-Madrona S; Girard TD; Godoy LC; Goodman AL; Goossens H; Green C; Greenstein YY; Gross PL; Hamburg NM; Haniffa R; Hanna G; Hanna N; Hegde SM; Hendrickson CM; Hite RD; Hindenburg AA; Hope AA; Horowitz JM; Horvat CM; Hudock K; Hunt BJ; Husain M; Hyzy RC; Iyer VN; Jacobson JR; Jayakumar D; Keller NM; Khan A; Kim Y; Kindzelski AL; King AJ; Knudson MM; Kornblith AE; Krishnan V; Kutcher ME; Laffan MA; Lamontagne F; Le Gal G; Leeper CM; Leifer ES; Lim G; Lima FG; Linstrum K; Litton E; Lopez-Sendon J; Lopez-Sendon Moreno JL; Lother SA; Malhotra S; Marcos M; Saud Marinez A; Marshall JC; Marten N; Matthay MA; McAuley DF; McDonald EG; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Moore SC; Morillo Guerrero R; Mouncey PR; Murthy S; Nair GB; Nair R; Nichol AD; Nunez-Garcia B; Pandey A; Park PK; Parke RL; Parker JC; Parnia S; Paul JD; Pérez González YS; Pompilio M; Prekker ME; Quigley JG; Rost NS; Rowan K; Santos FO; Santos M; Olombrada Santos M; Satterwhite L; Saunders CT; Schutgens REG; Seymour CW; Siegal DM; Silva DG; Shankar-Hari M; Sheehan JP; Singhal AB; Solvason D; Stanworth SJ; Tritschler T; Turner AM; van Bentum-Puijk W; van de Veerdonk FL; van Diepen S; Vazquez-Grande G; Wahid L; Wareham V; Wells BJ; Widmer RJ; Wilson JG; Yuriditsky E; Zampieri FG; Angus DC; McArthur CJ; Webb SA; Farkouh ME; Hochman JS; Zarychanski R
    N Engl J Med; 2021 Aug; 385(9):790-802. PubMed ID: 34351721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19.
    Mennuni MG; Renda G; Grisafi L; Rognoni A; Colombo C; Lio V; Foglietta M; Petrilli I; Pirisi M; Spinoni E; Azzolina D; Hayden E; Aimaretti G; Avanzi GC; Bellan M; Cantaluppi V; Capponi A; Castello LM; D'Ardes D; Corte FD; Gallina S; Krengli M; Malerba M; Pierdomenico SD; Savoia P; Zeppegno P; Sainaghi PP; Cipollone F; Patti G;
    J Thromb Thrombolysis; 2021 Oct; 52(3):782-790. PubMed ID: 33649979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
    Ortega-Paz L; Galli M; Capodanno D; Franchi F; Rollini F; Bikdeli B; Mehran R; Montalescot G; Gibson CM; Lopes RD; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):677-686. PubMed ID: 34519777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
    Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
    Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.